Supernus Pharmaceuticals (SUPN) Competitors $36.12 +0.59 (+1.66%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SUPN vs. KNSA, OCUL, INVA, ARQT, ORIC, JAZZ, CORT, PRGO, PCRX, and OMERShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), ORIC Pharmaceuticals (ORIC), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry. Supernus Pharmaceuticals vs. Kiniksa Pharmaceuticals Ocular Therapeutix Innoviva Arcutis Biotherapeutics ORIC Pharmaceuticals Jazz Pharmaceuticals Corcept Therapeutics Perrigo Pacira BioSciences Omeros Supernus Pharmaceuticals (NASDAQ:SUPN) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends. Which has preferable valuation and earnings, SUPN or KNSA? Kiniksa Pharmaceuticals has lower revenue, but higher earnings than Supernus Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$607.52M3.28$1.32M$1.0733.76Kiniksa Pharmaceuticals$270.26M5.67$14.08M-$0.14-151.49 Is SUPN or KNSA more profitable? Supernus Pharmaceuticals has a net margin of 9.16% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Supernus Pharmaceuticals' return on equity of 7.79% beat Kiniksa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals9.16% 7.79% 5.67% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Which has more risk & volatility, SUPN or KNSA? Supernus Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Does the MarketBeat Community prefer SUPN or KNSA? Supernus Pharmaceuticals received 303 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 72.99% of users gave Supernus Pharmaceuticals an outperform vote while only 64.89% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSupernus PharmaceuticalsOutperform Votes47372.99% Underperform Votes17527.01% Kiniksa PharmaceuticalsOutperform Votes17064.89% Underperform Votes9235.11% Does the media prefer SUPN or KNSA? In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 4 mentions for Supernus Pharmaceuticals and 0 mentions for Kiniksa Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.50 beat Kiniksa Pharmaceuticals' score of 0.49 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Supernus Pharmaceuticals Very Positive Kiniksa Pharmaceuticals Neutral Do analysts rate SUPN or KNSA? Supernus Pharmaceuticals currently has a consensus price target of $36.00, suggesting a potential downside of 0.33%. Kiniksa Pharmaceuticals has a consensus price target of $36.60, suggesting a potential upside of 72.56%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in SUPN or KNSA? 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 9.3% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummarySupernus Pharmaceuticals beats Kiniksa Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99B$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio33.764.8587.8613.46Price / Sales3.28374.821,228.8287.66Price / Cash22.4252.5939.5136.27Price / Book1.9810.216.946.30Net Income$1.32M$153.61M$119.12M$225.93M7 Day Performance-0.17%-2.00%-1.84%-1.32%1 Month Performance7.28%-7.47%-3.65%0.60%1 Year Performance32.65%31.80%31.64%26.23% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals2.3042 of 5 stars$36.12+1.7%$36.00-0.3%+32.3%$1.99B$607.52M33.76580Positive NewsKNSAKiniksa Pharmaceuticals1.9939 of 5 stars$21.21+1.9%$36.60+72.6%+33.9%$1.53B$270.26M0.00220OCULOcular Therapeutix3.7464 of 5 stars$8.89+1.3%$16.71+88.0%+273.6%$1.40B$58.44M0.00267INVAInnoviva1.2975 of 5 stars$19.15+0.3%N/A+40.6%$1.20B$310.46M27.75112News CoverageHigh Trading VolumeARQTArcutis Biotherapeutics1.7417 of 5 stars$10.17-0.1%$15.50+52.4%+391.8%$1.19B$59.61M0.00150ORICORIC Pharmaceuticals4.1915 of 5 stars$8.74-1.7%$18.29+109.2%+22.4%$616.78MN/A-4.8680Analyst RevisionJAZZJazz Pharmaceuticals4.9183 of 5 stars$122.00+2.3%$175.33+43.7%-1.2%$7.38B$3.83B16.792,800Analyst ForecastCORTCorcept Therapeutics4.6673 of 5 stars$55.00-1.9%$65.25+18.6%+116.2%$5.76B$482.38M44.52300PRGOPerrigo4.9798 of 5 stars$27.15-0.3%$37.00+36.3%-10.8%$3.70B$4.66B-23.209,140Positive NewsPCRXPacira BioSciences3.9929 of 5 stars$17.03+1.8%$23.50+38.0%-38.5%$786.28M$674.98M-8.39720Positive NewsOMEROmeros3.6817 of 5 stars$6.03flat$9.00+49.3%+244.6%$349.44MN/A-2.61198Analyst Upgrade Related Companies and Tools Related Companies KNSA Alternatives OCUL Alternatives INVA Alternatives ARQT Alternatives ORIC Alternatives JAZZ Alternatives CORT Alternatives PRGO Alternatives PCRX Alternatives OMER Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SUPN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
